Exécution de notre outil de synthèse sur un nouvel article
Vérifiez l’article ci-dessous, puis lancez sa synthèse.
Microbiome meets immunotherapy: unlocking the hidden predictors of immune checkpoint inhibitors
Lihaoyun Huang (Zhujiang Hospital, Kangda College of Nanjing Medical University), Haijun Yu (Zhujiang Hospital, Kangda College of Nanjing Medical University), Chunyan Zhang (Zhujiang Hospital, Southern Medical University), Aimin Jiang (Second Military Medical University, Changhai Hospital), Lingxuan Zhu (Zhujiang Hospital, Southern Medical University), Weiming Mou (Shanghai Jiao Tong University, Zhujiang Hospital), Kailai Li (Zhujiang Hospital, Southern Medical University), Jian Zhang (Zhujiang Hospital, Southern Medical University), Cui Cui (Zhujiang Hospital, Southern Medical University), Xinfang Cui (Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China), Anqi Lin (Zhujiang Hospital, Kangda College of Nanjing Medical University), Peng Luo (Zhujiang Hospital, Kangda College of Nanjing Medical University), Ting Wei (Zhujiang Hospital, Southern Medical University)
Résumé : Immune checkpoint inhibitors (ICIs) have revolutionized cancer immunotherapy, with the microbiome significantly influencing treatment outcomes. Analysis of 4663 studies (2014.01-2024.10) identified 71 eligible randomized controlled trials (RCTs) and cohort studies (41 viral, 30 bacterial). Analyses included subgroup assessments by cancer type, microbial taxa, and ICI regimens. Among 4663 identified studies, 71 met inclusion criteria (41 viral, 30 bacterial). Viral status, particularly hepatitis B virus (HBV) and human papillomavirus (HPV), significantly associated with ORR and DCR. Bacterial enrichment correlated with improved survival in hepatobiliary (OS: HR = 4.33, 95%CI: 2.20-8.50) and lung cancers (PFS: HR = 1.70, 95%CI: 1.04-2.78). Multi-microbiome models demonstrated superior outcome prediction, with microbial diversity correlating with improved PFS (HR = 0.64, 95%CI: 0.42-0.98). Viral status showed cancer-specific associations with SAEs. The microbiome serves as a valuable predictor of ICI outcomes. Future studies should emphasize large-scale RCTs, standardized assessment methods, and host-microbiome interactions.